# Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-for-biologics-and-conjugated-products-draft-guidance/c281f7a3-ef1f-4ee6-a357-dcddce26d99b

> FDA guidance document: Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance. Issue date: May 29, 2026. Get complete insights and analysis.

---

## Details

- Title: Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2026-05-29
- Comment Close Date: 2026-07-30
- Last Changed: 2026-05-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2026- D-2839">FDA-2026- D-2839</a>

## Related Documents

- [Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry/8d88c301-3351-40b1-9d30-132f12e70b07)
- [Monoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/monoclonal-antibodies-streamlined-nonclinical-safety-studies-draft-guidance-for-industry/439cec36-0e7d-4c02-88e4-7a0af7b47fa4)
- [Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development-draft-guidance-for-industry/401e294a-8da1-4a1d-9457-e02da07a92af)